SRRA - Sierra Oncology, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
1.89
+0.01 (+0.53%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close2.00
Open1.89
Bid1.80 x 2000
Ask2.15 x 1000
Day's Range1.81 - 1.92
52 Week Range1.10 - 4.09
Volume270,814
Avg. Volume583,011
Market Cap134.937M
Beta2.36
PE Ratio (TTM)N/A
EPS (TTM)-0.84
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.97
Trade prices are not sourced from all markets
  • CNW Group4 days ago

    Sierra Late-Breaking Data Demonstrating SRA737 Preclinical Activity with PARPi to be Presented at the AACR 2018 Annual Meeting

    Sierra Late-Breaking Data Demonstrating SRA737 Preclinical Activity with PARPi to be Presented at the AACR 2018 Annual Meeting

  • CNW Grouplast month

    Sierra Oncology to Present at the Future Leaders in the Biotech Industry Conference in New York

    Sierra Oncology to Present at the Future Leaders in the Biotech Industry Conference in New York

  • PR Newswirelast month

    Sierra Oncology to Present at the Future Leaders in the Biotech Industry Conference in New York

    VANCOUVER, March 19, 2018 /PRNewswire/ - Sierra Oncology, Inc. (SRRA), a clinical stage drug development company focused on advancing next generation DNA Damage Response (DDR) therapeutics for the treatment of patients with cancer, today announced that Dr. Angie You, Chief Business & Strategy Officer, Head of Commercial, will present an overview of the company at the Future Leaders in the Biotech Industry Conference being held in New York. A live audio webcast and archive of the presentation will be accessible through the Sierra Oncology website at www.sierraoncology.com. Sierra Oncology is a clinical stage drug development company advancing next generation DDR therapeutics for the treatment of patients with cancer.

  • PR Newswirelast month

    Late-Breaking Abstract Reporting SRA737 Preclinical Activity in CCNE1-Driven and PARPi-Resistant Cancers Accepted for AACR 2018 Annual Meeting

    VANCOUVER , March 14, 2018 /PRNewswire/ - Sierra Oncology, Inc. (Nasdaq: SRRA), a clinical stage drug development company focused on advancing next generation DNA Damage Response (DDR) therapeutics for ...

  • CNW Grouplast month

    Late-Breaking Abstract Reporting SRA737 Preclinical Activity in CCNE1-Driven and PARPi-Resistant Cancers Accepted for AACR 2018 Annual Meeting

    Late-Breaking Abstract Reporting SRA737 Preclinical Activity in CCNE1-Driven and PARPi-Resistant Cancers Accepted for AACR 2018 Annual Meeting

  • PR Newswire2 months ago

    Sierra Oncology Announces Pricing of Public Offering of Common Stock

    VANCOUVER, March 2, 2018 /PRNewswire/ - Sierra Oncology, Inc. (SRRA), a clinical stage drug development company focused on advancing next generation DNA Damage Response therapeutics for the treatment of patients with cancer, today announced the pricing of an underwritten public offering of 19,000,000 shares of its common stock at a price of $2.25 per share, with expected gross proceeds to Sierra Oncology of $42,750,000. In addition, Sierra Oncology has granted the underwriters a 30-day option to purchase up to 2,850,000 additional shares of common stock at the public offering price, less underwriting discounts and commissions. Sierra Oncology intends to use the net proceeds from the public offering to fund development of its product candidates, SRA737 and SRA141, as well as for general corporate purposes.

  • CNW Group2 months ago

    Sierra Oncology Announces Pricing of Public Offering of Common Stock

    Sierra Oncology Announces Pricing of Public Offering of Common Stock

  • PR Newswire2 months ago

    Sierra Oncology Announces Proposed Public Offering of Common Stock

    VANCOUVER, March 1, 2018 /PRNewswire/ - Sierra Oncology, Inc. (SRRA), a clinical stage drug development company focused on advancing next generation DNA Damage Response therapeutics for the treatment of patients with cancer, today announced that it intends to offer and sell, subject to market conditions, shares of its common stock in an underwritten public offering. All of the shares to be sold in the offering will be offered by Sierra Oncology. In addition, Sierra Oncology intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the public offering.

  • CNW Group2 months ago

    Sierra Oncology Announces Proposed Public Offering of Common Stock

    Sierra Oncology Announces Proposed Public Offering of Common Stock

  • 5 Biotech Stocks to Sell Amid the Latest Slaughter
    InvestorPlace2 months ago

    5 Biotech Stocks to Sell Amid the Latest Slaughter

    Stocks are under fresh pressure after new Federal Reserve chairman Jerome Powell sounded a hawkish note in his first appearance before Congress this week. The odds of four quarter-point rate hikes is now rising fast, pressuring long-term Treasury yields higher, bringing back the headwind that pushed stocks into a correction earlier this month.

  • PR Newswire2 months ago

    Sierra Oncology Reports 2017 Year End Results

    - Janssen supply agreement for ZEJULA® (niraparib) facilitates novel PARPi combination trial with SRA737 in prostate cancer - - SRA737 clinical development program significantly expanded - - SRA737 clinical ...

  • CNW Group2 months ago

    Sierra Oncology Reports 2017 Year End Results

    Sierra Oncology Reports 2017 Year End Results

  • CNW Group2 months ago

    Sierra Oncology Significantly Expands Clinical Development Program

    Sierra Oncology Significantly Expands Clinical Development Program

  • PR Newswire2 months ago

    Sierra Oncology Significantly Expands Clinical Development Program

    VANCOUVER, Feb. 27, 2018 /PRNewswire/ - Sierra Oncology, Inc. (SRRA), a clinical stage drug development company focused on advancing next generation DNA Damage Response (DDR) therapeutics for the treatment of patients with cancer, today reported significant progress in the advancement of its strategic pipeline of drug assets. The company announced noteworthy progress in the Dose Escalation Phase 1 portions for both of its ongoing Phase 1/2 clinical trials evaluating its potential best-in-class Chk1 inhibitor, SRA737.

  • CNW Group2 months ago

    Sierra Oncology and Janssen Sign Supply Agreement for Prostate Cancer Study

    Sierra Oncology and Janssen Sign Supply Agreement for Prostate Cancer Study

  • PR Newswire2 months ago

    Sierra Oncology and Janssen Sign Supply Agreement for Prostate Cancer Study

    VANCOUVER, Feb. 27, 2018 /PRNewswire/ - Sierra Oncology, Inc. (SRRA), a clinical stage drug development company focused on advancing next generation DNA Damage Response (DDR) therapeutics for the treatment of patients with cancer, today announced the signing of a clinical supply agreement with Janssen Research & Development, LLC. (Janssen) for access to TESARO's ZEJULA® (niraparib), an orally administered poly (ADP-ribose) polymerase (PARP) inhibitor undergoing clinical development by Janssen for patients with prostate cancer. Sierra intends to evaluate its Chk1 inhibitor, SRA737, in combination with niraparib in patients with metastatic castration-resistant prostate cancer (mCRPC).

  • PR Newswire2 months ago

    Sierra to Report Preclinical Data Demonstrating SRA737 Synergy with PARPi at the AACR 2018 Annual Meeting

    VANCOUVER, Feb. 21, 2018 /PRNewswire/ - Sierra Oncology, Inc. (SRRA), a clinical stage drug development company focused on advancing next generation DNA Damage Response (DDR) therapeutics for the treatment of patients with cancer, today announced it has been accepted to present preclinical data demonstrating that its Chk1 inhibitor, SRA737, synergizes with niraparib, a poly ADP-ribose inhibitor (PARPi), in a poster at the American Association of Cancer Research (AACR) Annual Meeting 2018 being held in Chicago, Illinois from April 14-18. Notably, this combination was effective in homologous repair proficient tumor cell lines where PARP inhibitors are substantially less active in the clinical setting," said Dr. Christian Hassig, Chief Scientific Officer of Sierra Oncology.

  • CNW Group2 months ago

    Sierra to Report Preclinical Data Demonstrating SRA737 Synergy with PARPi at the AACR 2018 Annual Meeting

    Sierra to Report Preclinical Data Demonstrating SRA737 Synergy with PARPi at the AACR 2018 Annual Meeting

  • PR Newswire2 months ago

    Sierra Oncology to host Program Update in New York on February 27th

    VANCOUVER, Feb. 6, 2018 /PRNewswire/ - Sierra Oncology, Inc. (SRRA), a clinical stage drug development company focused on advancing next generation DNA Damage Response (DDR) therapeutics for the treatment of patients with cancer, today announced it will host a Program Update on Tuesday, February 27th from 10:00 a.m. – 12:00 p.m. Eastern Time (ET) at the Lotte New York Palace in New York, NY. The company will be joined by Dr. Udai Banerji, Chief Investigator for Sierra's ongoing SRA737 Phase 1/2 clinical studies, and Dr. Alan D'Andrea, a member of Sierra's DDR Advisory Committee.

  • CNW Group2 months ago

    Sierra Oncology to host Program Update in New York on February 27th

    Sierra Oncology to host Program Update in New York on February 27th

  • PR Newswire3 months ago

    Sierra Oncology to Present at the DNA Damage Response Therapeutics Summit

    VANCOUVER, Jan. 29, 2018 /PRNewswire/ - Sierra Oncology, Inc. (SRRA), a clinical stage drug development company focused on advancing next generation DNA Damage Response (DDR) therapeutics for the treatment of patients with cancer, today announced that its Chief Medical Officer, Dr. Mark Kowalski, will present "Leveraging Synthetic Lethality to Enhance Clinical Trials with SRA737, a Next-Generation Chk1 Inhibitor" at the DNA Damage Response Therapeutics Summit in Boston, MA. Sierra Oncology is a key sponsor of the DNA Damage Response Therapeutics Summit, which will gather leading stakeholders from across drug development over two days to discuss how to therapeutically exploit synthetic lethal interactions for targeted cancer therapy.

  • CNW Group3 months ago

    Sierra Oncology to Present at the DNA Damage Response Therapeutics Summit

    Sierra Oncology to Present at the DNA Damage Response Therapeutics Summit

  • SmarterAnalyst3 months ago

    4 Biotechs with Near Term Catalysts: G1 Therapeutics, Inc. (GTHX), Sierra Oncology Inc (SRRA), Myokardia Inc (MYOK), Jounce Therapeutics (JNCE)

    The company’s lead asset, Trilaciclib, is currently being evaluated in a number of settings as a tack-on to the standard of care in both front line and 2nd-3rd lines of small cell lung cancer (SCLC) and triple-negative breast cancer (TNBC). CDK4/6 keeps cells in stasis, known as the G1 phase of the cell cycle, rendering it difficult to undergo cell division.

  • PR Newswire4 months ago

    Sierra Oncology to Present at the Biotech Showcase in San Francisco

    VANCOUVER, Jan. 3, 2018 /PRNewswire/ - Sierra Oncology, Inc. (SRRA), a clinical stage drug development company focused on advancing next generation DNA Damage Response (DDR) therapeutics for the treatment of patients with cancer, today announced that Dr. Nick Glover, President and Chief Executive Officer, will present an overview of the company at the Biotech Showcase being held in San Francisco on January 8-10. A live audio webcast and archive of the presentation will be accessible through the Sierra Oncology website at www.sierraoncology.com. Sierra Oncology is a clinical stage drug development company advancing next generation DNA Damage Response (DDR) therapeutics for the treatment of patients with cancer.

  • CNW Group4 months ago

    Sierra Oncology to Present at the Biotech Showcase in San Francisco

    Sierra Oncology to Present at the Biotech Showcase in San Francisco